The Efficacy of Ibrutinib Plus Venetoclax for the Treatment of R/R MCL
Constantine Tam, MD, discuses the outcomes of the phase 3 Sympatico Study, which evaluated the safety and efficacy of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for the treatment of relapsed or refractory mantle cell lymphoma compared to monotherapy.
Constantine Tam, MD, leader of the Chronic Lymphocytic Leukemia and Low-Grade Lymphoma Program at the Peter MacCallum Cancer Centre, discuses the outcomes of the phase 3 Sympatico Study, which evaluated the safety and efficacy of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for the treatment of relapsed or refractory mantle cell lymphoma compared to monotherapy. Results were presented at the 2020 American Society of Hematology (ASH) Annual Meeting and Exposition.
The study evaluated 21 patients, 15 of whom were at high risk for tumor lysis syndrome. According to Tam, the overall response rate was 81% and the complete response rate was 62%. The median progression-free survival at 18 months was 75%.
The combination proved to have acceptable levels of toxicity and induced durable responses. It was also more effective than either therapy on its own, according to Tam. Additionally, only 1 case of tumor lysis syndrome occurred.
